Skip to main content
ArticleOPEN ACCESS

Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: Results of monotherapy and combination therapy trials

Drug Design, Development and Therapy
DOI: 10.2147/DDDT.S156746
3Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Cite

CITATION STYLE

APA

Alecu, I., Milenkova, T., & Turner, S. R. (2018, February 21). Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: Results of monotherapy and combination therapy trials. Drug Design, Development and Therapy. Dove Medical Press Ltd. https://doi.org/10.2147/DDDT.S156746

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free